Santen Pharmaceutical (OTCMKTS:SNPHY) Stock Price Down 8.5% – Should You Sell?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was down 8.5% during trading on Friday . The stock traded as low as $11.59 and last traded at $11.59. Approximately 455 shares changed hands during trading, a decline of 96% from the average daily volume of 11,254 shares. The stock had previously closed at $12.67.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold”.

Santen Pharmaceutical Stock Performance

The stock has a 50 day moving average price of $12.48 and a two-hundred day moving average price of $11.52. The company has a market capitalization of $3.89 billion and a PE ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.